Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

Transaction worth based connected SEC Form 4 weighted mean merchantability terms ($21.20); post-transaction worth based connected April 7, 2026, marketplace adjacent ($19.80).

• What was the operation of this transaction?
  The transaction progressive the workout of 27,000 banal options astatine a onslaught terms of $5.20, with each underlying shares sold instantly astatine a weighted-average terms of $21.20 -- truthful determination was nary summation successful nett equity exposure. All 4 of Adam's caller transactions were executed pursuant to a Rule 10b5-1 trading program adopted connected Oct. 27, 2025, meaning they were pre-scheduled good successful advance.

• How does the standard of this merchantability comparison to Adam's anterior trading activity?
  SEC filings corroborate that the April 1 transaction was the 4th successful a bid of income by Adam nether her 10b5-1 plan, spanning precocious February done aboriginal April 2026. The mean transaction size crossed each 4 income is astir 28,000 shares, making the April 1 merchantability of 27,000 shares astir successful enactment with Adam's caller signifier of activity.

• What does the transaction amusement astir remaining equity exposure?
  Following the April 1 sale, Adam holds 112,622 communal shares and retains 433,500 banal options. That important enactment equilibrium provides important ongoing vulnerability to the company’s show and leaves country for aboriginal conversions.

* 1-year show calculated utilizing April 7, 2026, arsenic the notation date.

Tango Therapeutics is simply a clinical-stage biotechnology institution specializing successful the find and improvement of precision oncology therapies.

• Lead objective campaigner is vopimetostat (TNG462), a once-daily oral PRMT5 inhibitor targeting MTAP-deleted cancers, presently successful Phase 1/2 dose enlargement crossed pancreatic, lung, and different non-CNS cancers, with a pivotal survey successful second-line pancreatic crab expected to motorboat successful 2026.

• Additional progressive objective programs see TNG456, a brain-penetrant PRMT5 inhibitor successful Phase 1/2 dose escalation for MTAP-deleted glioblastoma; and TNG260, a CoREST inhibitor successful Phase 1/2 dose enlargement for STK11-mutant/RAS wild-type lung cancer.

• Active collaborations see an ongoing operation survey with Revolution Medicines' RAS(ON) inhibitors successful MTAP-deleted pancreatic and lung cancer, and a objective proviso statement with Erasca announced March 5, 2026, to research vopimetostat successful operation with Erasca's pan-RAS molecular glue.